A practical reference on glucagon receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-18 and is reviewed periodically as new material appears.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Serum haptocorrin binds 80-90% of circulating B12, rendering it unavailable for cellular delivery by transcobalamin II. This is conjectured to be a circulating storage function. Several serious, even life-threatening diseases cause elevated serum haptocorrin, measured as abnormally high serum vitamin B12, while potentially manifesting as a symptomatic vitamin deficiency because of insufficient vitamin bound to transcobalamin II which transfers the vitamin to cells.
Explorations of artificial materials for manipulating electromagnetic waves began at the end of the 19th century. Some of the earliest structures that may be considered metamaterials were studied by Jagadish Chandra Bose, who in 1898 researched substances with chiral properties. Karl Ferdinand Lindman studied wave interaction with metallic helices as artificial chiral media in the early twentieth century. In the late 1940s, Winston E. Kock from AT&T Bell Laboratories developed materials that had similar characteristics to metamaterials. In the 1950s and 1960s, artificial dielectrics were studied for lightweight microwave antennas. Microwave radar absorbers were researched in the 1980s and 1990s as applications for artificial chiral media. Negative-index materials were first described theoretically by Victor Veselago in 1967. He proved that such materials could transmit light. He showed that the phase velocity could be made anti-parallel to the direction of Poynting vector. This is contrary to wave propagation in naturally occurring materials. In 1995, John M. Guerra fabricated a sub-wavelength transparent grating (later called a photonic metamaterial) having 50 nm lines and spaces, and then coupled it with a standard oil immersion microscope objective (the combination later called a super-lens ) to resolve a grating in a silicon wafer also having 50 nm lines and spaces. This super-resolved image was achieved with illumination having a wavelength of 650 nm in air.
The non-protein amino acid-accumulating clade, also known as the Canavanine-accumulating clade, is a clade of the flowering plant subfamily Faboideae (or Papilionoideae) that includes the majority of agriculturally-cultivated legumes. It is characterized by the accumulation of the non-proteinogenic amino acid canavanine in the seeds—a deterrent against herbivory. This phylogenetic trait was first recognized in the early 1980s. This clade is consistently resolved in molecular phylogenies. It contains many economically important genera, including Cicer, Glycine, Medicago, Phaseolus, Trifolium, Vicia, and Vigna.
, statistical functions introduced to match the assumed Gaussian distribution of asperities. Matthew Leighton et al. presented fits for crosshatched IC engine cylinder liner surfaces together with a process for determining the
Sources: en.wikipedia.org
=== Pharmacodynamics === Benorterone is an antiandrogen, or an antagonist of the androgen receptor (AR), the biological target of the androgen sex hormones testosterone and dihydrotestosterone. In one study, the affinity of benorterone for the AR was found to be about 5-fold greater than that of cyproterone acetate in rat prostate cytosol; the Ki values were 0.7 nM for benorterone and 3.7 nM for cyproterone acetate, which were 243% and 46% of those of testosterone (Ki = 1.7 nM), respectively. However, another study found that benorterone had only 11% of the affinity of dihydrotestosterone for the androgen receptor. Although an antiandrogen, benorterone actually is a very weak partial agonist of the AR and has been reported to possess weak androgenic activity. The same is true for cyproterone acetate and other steroidal antiandrogens. Unlike certain other steroidal antiandrogens such as cyproterone acetate, benorterone is not also a progestogen, instead being described as a selective and pure AR antagonist similarly to nonsteroidal antiandrogens such as flutamide and bicalutamide. However, although it is described as not being a progestogen, benorterone was found to produce "a highly variable decrease in plasma testosterone levels," indicating that it has weak antigonadotropic effects. The reasons for this are unclear, as other pure antiandrogens such as cyproterone (not cyproterone acetate) and flutamide do not do this and instead produce consistent increases in testosterone levels.
In 1992, whilst studying for his PhD, he also ran the London Marathon, in a time of 4 hours and 41 minutes, to raise money to buy a computer for a young boy with physical disabilities. Skinner's PhD involved developing genetic tests to detect congenital adrenal hyperplasia in children. He had work published in a number of scientific journals. In 1994 he had his work published in Human Molecular Genetics. In 1994, Skinner married Dr. Monica Schneider (also a molecular biologist), and in 1996 their son James was born. From 1994 to 1996 Skinner worked as a Post-Doctoral Research Fellow at Vanderbilt University Medical Center, in Nashville, Tennessee. The work he carried out there involved gene sequencing and protein purification of cytochrome P450 enzymes. His work was published in the Journal of Biological Chemistry. From 1996 to 1997 Skinner took care of his infant son, James, whilst his wife continued to work at Vanderbilt University Medical Center.
== Applications == Gas analysis: for determining small amounts of impurities or poisons in air. Other compounds can also be determined by this method (ozone, N-oxides, S-compounds). A typical example is NO determination with detection limits down to 1 ppb. Highly specialised chemiluminescence detectors have been used recently to determine concentrations as well as fluxes of NOx with detection limits as low as 5 ppt. Analysis of inorganic species in liquid phase Analysis of organic species: useful with enzymes, where the substrate is not directly involved in the chemiluminescence reaction, but the product is Detection and assay of biomolecules in systems such as ELISA and Western blots DNA sequencing using pyrosequencing Lighting objects. Chemiluminescence kites, emergency lighting, glow sticks (party decorations). Combustion analysis: Certain free radical species (such as •CH and •OH) give off radiation at specific wavelengths. The heat release rate is calculated by measuring the amount of light radiated from a flame at those wavelengths. Children's toys
Sam Camfield. Design Manager, South Western Railway. For services to the State Funeral of Her Majesty Queen Elizabeth II. William Wright Glover Campbell. Captain, 1st Stewarton Boys' Brigade. For services to the community in Stewarton, East Ayrshire. Bronwin Mary Carter. Paralympic Coach. For services to Sport. Christopher Charles Cassidy. Watchkeeper, Cabinet Office. For services to Civil Contingencies and to St John Ambulance. Ann Chapman. For services to the community in Radcliffe, Metropolitan Borough of Bury. Stephen Charnock. For services to the community in Newark, Nottinghamshire. Ian Raymond Clark. For services to the community in High Wycombe, Buckinghamshire. Roy Michael Claxton. Founder, Parkinson's Scottish Table Tennis Association. For services to People with Parkinson's Disease. Peter Stewart Clemson. Founder and Chair, Little Theatre Company. For services to the Performing Arts and to the community in Burton-on-Trent, Staffordshire. Judith Mary Climer. Founder, Michael Climer Legacy Fund. For services to the community in Caerphilly. Isobel Jennifer Clink. For services to Golf. Joy Henrietta Mary Coalter. Lately Building and Cleaning Supervisor, Brookeborough Primary School, County Fermanagh. For services to Education. Robert Coburn. Scottish Area Vice Chair, Royal Naval Association and Poppy Appeal Convenor. For voluntary service to Veterans and to the community in Inverness-shire (to be dated 27th November 2023). Dr Shara Cohen. Chief Executive Officer, Honnao Ltd. For voluntary services to Women in STEM and to Cancer Patients and their Families.
== Related compounds == Cyclohexanehexone can be viewed as the neutral counterpart of the rhodizonate anion C6O2−6. The singly charged anion C6O−6 has been detected in mass spectrometry experiments, formed by oligomerization of carbon monoxide through the formation of molybdenum carbonyls. According to X-ray diffraction analysis, the reagent traded under the name "cyclohexanehexone octahydrate" or equivalent names is actually dodecahydroxycyclohexane dihydrate—the geminal diol derivative of the six ketone groups with an additional two molecules of water—a solid that decomposes at 95 °C. In 1966, Howard E. Worne of Natick Chemical Industries patented compounds with formulas C10O8 and C14O10, which can be described as the fusion of two or three molecules of C6O6, claimed to be produced by the action of ultraviolet radiation on a hot water solution of the parent compound.
Sources: en.wikipedia.org
In general, pressure and chemical environment cause only small changes to fusion ratios. An early explanation invoked the Oppenheimer–Phillips process at low energies, but its magnitude was too small to explain the altered ratios.
In 1983, financier Marc Rich was accused of violating the act by trading in Iranian oil during the Iran hostage crisis. He was one of many people pardoned by President Bill Clinton in his last days in office. On August 23, 2006, Javed Iqbal was arrested through the U.S. Department of the Treasury with a charge of conspiracy to violate the IEEPA for airing material produced by al-Manar (The Beacon) in New York City during the 2006 Israel-Lebanon conflict. On December 16, 2009, it was announced that the U.S. Department of Justice reached a settlement with Credit Suisse over accusations that the bank assisted residents of IEEPA sanctioned countries to wire money in violation of the Act from 1995 to 2006. The settlement resulted in Credit Suisse forfeiting $536 million. On July 16, 2020, a UAE-based firm, Essentra FZE Company Limited, admitted of conspiring to violate the International Emergency Economic Powers Act (IEEPA) and defying the United States sanctions on North Korea. The firm also agreed to pay a fine of $665,112 to the United States Department of Justice.
Complete: Data should not be missing Consistent: Data should not deviate from a set style, for example, the abbreviation N/A should only be used for one phrase Enduring: Documents should be designed to last a reasonable length of time Available: Documents should be retrievable. GxPs require that a quality system be established, implemented, documented, and maintained. As explained above, documentation is a critical tool for ensuring GxP adherence. For more information, see good manufacturing practice.
=== Purpose === The purpose of single-cell transcriptomics is to determine what genes are being expressed in each individual cell. The transcriptome is often used to quantify gene expression instead of the proteome because of the difficulty currently associated with amplifying protein levels sufficiently to make them convenient to study. There are three major reasons gene expression has been studied using this technique: to study gene dynamics, RNA splicing, and for cell typing. Gene dynamics are usually studied to determine what changes in gene expression affect different cell characteristics. For example, this type of transcriptomic analysis has often been used to study embryonic development. RNA splicing studies are focused on understanding the regulation of different transcript isoforms. Single-cell transcriptomics has also been used for cell typing, where the genes expressed in a cell are used to identify and classify different types of cells. The main goal in cell typing is to find a way to determine the identity of cells that do not express known genetic markers. RNA expression can serve as a proxy for protein abundance. However, protein abundance is governed by the complex interplay between RNA expression and post-transcriptional processes. While more challenging technically, translation can be monitored by ribosome profiling in single cells.
4-Fluoroselegiline, or p-fluoro-L-deprenyl, is a substituted amphetamine designer drug. It is the enantiopure L- enantiomer of 4-fluorodeprenyl and the 4-fluorinated derivative of selegiline (L-deprenyl).
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.